Biological responses to Hepatocyte Growth Factor are mediated by the tyrosine kinase receptor encoded by the Met oncogene. Under physiological conditions, Met triggers a multi-step genetic program called`invasive growth' including cell-dissociation, invasion of extracellular matrices and growth. When constitutively activated, Met can induce cell transformation and metastasis. Phosphorylation of two docking tyrosines in the receptor tail is essential for all biological responses. To investigate the role of the C-terminal part of Met, we have generated mutants lacking either the last 26 or 47 amino acids. As expected, mutants lacking the docking sites fail to mediate cell transformation and invasion. Interestingly, while Met D26 can mediate invasion, its transforming ability is severely impaired. Moreover, the lack of the last 26 amino acids strongly reduces Met ability to phosphorylate substrates in vitro and in vivo. These data indicate that the last 26 amino acids are required to confer the kinase its full enzymatic activity, which is critical for cell transformation but dispensable for invasive properties. Finally, we also show that upregulation of Met enzymatic activity by insertion of a point mutation in the kinase domain (M1250T) overcomes the regulatory role played by the last 26 amino acids of the tail. It is concluded that the C-terminal domain of Met is crucial not only for recruitment of transducers but also for regulation of receptor enzymatic activity. Oncogene (2001) 20, 5493 ± 5502.
Introduction
The biological eects of Hepatocyte Growth Factor (HGF) are mediated by Met, its tyrosine kinase receptor. As a result of stimulation of cell-dissociation, motility and polarization, HGF induces the formation of three-dimensional branched tubular structures (Montesano et al., 1991) . This biological response, called`invasive cell growth', is essential for mouse development. Indeed, HGF and Met null mice display an embryonic lethal phenotype due to defects in implantation of placenta, liver development and migration of myoblasts Schmidt et al., 1995; Uehara et al., 1995) .
Met was originally identi®ed as a transforming sequence activated by chromosomal rearrangement (Cooper et al., 1984; Park et al., 1986) . The resulting oncogene (Tpr-Met) encodes a fusion protein where Tpr sequences, replacing the extracellular, transmembrane and juxtamembrane domains of Met, provide two strong dimerization motifs (Rodrigues and Pack, 1993) . Dimerization results in constitutive activation of the Met kinase, which acquires transforming potential. The involvement of Met receptor in human tumors has also been documented. Met overexpression has been detected in many dierent tumors such as papillary thyroid carcinomas and ovarian carcinomas (Di Renzo et al., 1992 . A more direct link between Met and human cancer has been demonstrated in hereditary papillary renal carcinomas (HPRC) where several germline missense mutations in the MET gene have been identi®ed (Schmidt et al., 1997 (Schmidt et al., , 1998 . All mutations are located in the kinase domain. Among these, the M1250T mutation leads to up regulation of kinase activity and confers transforming ability . Met M1250T -mediated cell transformation correlates with the hyper-activation of the Ras signaling pathway (Giordano et al., 2000) .
Met has a dimeric structure, consisting of an extracellular a-subunit, disulphide-linked to a transmembrane b-subunit. Ligand binding activates the cytoplasmic tyrosine kinase activity, leading to autophosphorylation of the receptor and to phosphorylation of cellular substrates. Schematically, the Met cytoplasmic region can be divided into three functional domains. The juxtamembrane domain negatively regulates Met activity. The phosphorylation of serine 975 by PKC or Ca 2+ /Calmodulin-dependent kinase and/or the recruitment of a cytoplasmic tyrosine phosphatase by the phosphorylated tyrosine 1003 inhibit Met kinase activity (Gandino et al., 1990 (Gandino et al., , 1994 Villa-Moruzzi et al., 1993) . The kinase domain contains two tyrosines (Y 1234 and Y 1235 ). Phosphorylation of these major autophosphorylation sites positively regulates the enzymatic activity of the Met kinase Longati et al., 1994; Naldini et al., 1991) . The C-terminal domain contains a two-tyrosine docking site (Y 1349 and Y 1356 ) which, upon phosphorylation, binds multiple SH2-containing transducers, including phosphatidylinositol 3-kinase (Graziani et al., 1991) , phospholipase C-g, SRC, the adaptors Grb2 and SHC (Pelicci et al., 1995) , the transcriptional factor STAT-3 (Boccaccio et al., 1998) , and the docking protein Gab1 (Grb2-associated binder 1) (Weidner et al., 1996) . This`multifunctional docking site' is essential for Met-mediated responses. The substitution of both tyrosines with phenylalanine abolishes the HGF-mediated responses both in vitro and in vivo Maina et al., 1996) .
While the role of the`multifunctional docking site' of Met and of the other members of the Met family (Ron and c-Sea) has been largely elucidated Park and Hayman, 1999; Xiao et al., 2000) , the role of the last domain of the Met tail (26 amino acids localized after the docking site) has not yet been determined. The low homology of the amino-acid sequence between this domain and the corresponding domain of Ron, suggests that it might play a speci®c role in Met signal transduction and could explain the speci®city of receptor-induced responses. Indeed, while Met and Ron mediate invasion (Montesano et al., 1991; Medico et al., 1996) , cell transformation is elicited only by Met (Santoro et al., 1996) .
In the present study, we show that this domain positively regulates Met kinase activity and that its presence is critical for the transforming ability but not for Met-mediated invasiveness. Moreover, we also show that the physiological role of this domain can be substituted by the insertion of a point mutation (M1250T) in the Met kinase domain, which is known to up-regulate the kinase activity and interfere with the receptor auto-inhibition mechanisms.
Results
The last 26 amino acids of the Met tail positively regulate receptor kinase activity
To study the role of the C-terminal part of Met for its enzymatic activity, we constructed deletion mutants lacking either the last 26 or 47 amino acids of the b-subunit (Figure 1a ). Expression vectors containing wild type or deleted forms of Met were transfected into NIH3T3 cells and cells lines stably expressing the exogenous proteins were established (Figure 1b) . The level of in vivo tyrosine phosphorylation of wild type and mutant Met receptors was determined by immunoprecipitation with anti-Met antibodies, followed by Western blotting with an antiphosphotyrosine antibody. The total level of Met protein was determined by stripping the membrane and reprobing it with speci®c antibodies. While the phosphorylation levels of Met wild type and Met D26 are not signi®cantly dierent, Met D47 displayed a lower level of phosphorylation. This observation could be explained by the fact that Met D47 lacks three autophosphorylation sites (Y1349, Y1356 and Y1365).
Then, we measured the ability of these receptors to phosphorylate an exogenous substrate: the Myelin Basic Protein (MBP) (Figure 1c ). The deletion of the last 47 amino acids resulted in a 46+13% increase of the Met ability to phosphorylate MBP in vitro compared to the wild type. This indicates that this domain negatively regulates the Met kinase activity since its deletion leads to the increase of enzymatic activity. In agreement with this observation, it has been recently shown that a cell-permeable peptide derived from the Met tail and containing the docking site binds to the receptor and inhibits its kinase activity . Surprisingly, the deletion of the last 26 amino acids resulted in a 35.3+11% reduction of the Met ability to phosphorylate MBP, compared to wild type, indicating that the last portion of the receptor tail positively regulates the tyrosine kinase activity.
All together these data show that the C-terminal part of Met contains two regulatory domains, displaying con¯icting behaviour on the receptor kinase activity.
The last 26 amino acids of Met tail are dispensable for Met-mediated cell scattering and tubulogenesis MLP29 cells, expressing Met but not the NGF receptor (Trk-A), form tight epithelial monolayers with junctional complexes. Met activation induces the disruption of intercellular junctions and stimulates cell motility. Moreover, in response to HGF, MLP29 cells migrate in three dimensional collagen gels and form long and branched tubules (Medico et al., 1996) . To study the role played by the C-terminal domain of Met in these speci®c responses, we generated chimeric proteins containing the extracellular and the transmembrane domains of the NGF receptor (Trk-A) fused to full (Trk-Met Wt) or deleted intracellular domains of Met (Trk-Met D26 and Trk-Met D47). Expression vectors containing either wild type or deleted forms of TrkMet were transfected into MLP29 cells and cells lines expressing the exogenous proteins were established. A cell line transfected with the empty vector was used as a negative control. Then, we investigated the role of the C-terminal portion of Met for receptor-mediated invasiveness (cell scattering and tubulogenesis). As shown in Figure 2a , cell-cell dissociation is observed in cells expressing Trk-Met wild type or Trk-Met D26. As expected, Met mediated cell scattering is abolished in cells expressing the Trk-Met D47, indicating the absolute requirement of the docking site for this biological response. We also tested the ability of these cells to form tubules in collagen. Similarly, cells expressing Trk-Met wild type or Trk-Met D26 were able to form tubules in the presence of NGF, whereas cells expressing Trk-Met D47 and control cells formed only cysts (Figure 2b) .
The docking protein Gab1 is known to play a critical role in these receptor-induced responses. It has been shown that Gab1 overexpression mimics HGFmediated cell scattering and branching tubulogenesis (Weidner et al., 1996) . For this, we determined whether wild type and deleted forms of Trk-Met, activated in response to NGF, were able to interact with Gab1. As shown in Figure 3 , Trk-Met D47, which lacks the docking site, did not interact with GST-Gab1. In contrast, Trk-Met wild type and Trk-Met D26 were pulled down with the same eciency, indicating that the deletion of the last 26 amino acids alters neither docking site phosphorylation nor Met transducer recruitment.
These results show that the last 26 amino acids of the Met tail are dispensable for invasiveness.
The last 26 amino acids of Tpr-Met play an important role in Tpr-Met-mediated cell transformation
The constitutive activation of the Met kinase, as in the case of Tpr-Met, leads to cell transformation. It has been shown that Gab1 plays an important role for this biological activity (Ponzetto et al., 1996; Rodrigues et , 1997; Weidner et al., 1996; Korhonen et al., 1999; Garcia-Guzman et al., 1999; Itoh et al., 2000; Schaeper et al., 2000) and a direct correlation between Gab1 phosphorylation and Tpr-Met-mediated cell transformation has been observed (Bardelli et al., 1997; Fixman et al., 1997) .
The role of the C-terminal part of Met b subunit in this biological response was assessed by focus formation in NIH3T3 cells. Cells were transfected with the expression vector pBabe containing either wild type or deleted Tpr-Met cDNAs. As a control, cells were also transfected with the empty vector. Foci Figure 2 The last 26 amino acids of Met are dispensable for scattering and tubulogenesis. (a) MLP29 cells expressing the dierent constructs were plated in DMEM containing 10% serum. The medium was changed after 5 h and HGF (100 units/ml) or NGF (100 ng/ml) were added as indicated. After 12 h, the cells were ®xed with glutheraldeyde and stained with crystal violet. (b) Tubulogenesis assays with MLP29 cells were performed as described in the Materials and methods section. (a) and (b) show representatives experiment performed in duplicate at least three times were scored 3 weeks after DNA transfer. As expected, Tpr-Met D47 failed to induce foci formation ( Figure  4a ), indicating that the docking site is required for this response. Interestingly, Tpr-Met D26, which has an intact docking site, induced the formation of fewer foci (59.6+15%) compared to Tpr-Met. One hypothesis to explain this dierence could be that the Cterminal portion of Met positively regulates the tyrosine kinase activity of Tpr-Met. The absence of this domain could thus decrease the ability of Tpr-Met to phosphorylate its substrates. Since Gab1 is the major substrate of Tpr-Met and Gab1-dependent signaling pathways are essential to mediate this response (Weidner et al., 1996; Bardelli et al., 1997; Fixman et al., 1997; Korhonen et al., 1999; GarciaGuzman et al., 1999; Itoh et al., 2000; Schaeper et al., 2000) , we determined the tyrosine phosphorylation of Gab1. As shown in Figure 4b , while Tpr-Met and Tpr-Met D26 were co-immunoprecipitated with Gab1 to a similar extent, Tpr-Met D26 phosphorylated Gab1 less eciently compared to Tpr-Met. This is also shown by the analysis of Gab1 electrophoretic migration that correlates to the level of Met kinase activity. Gab1 mobility was reduced on Tpr-Met wild type phosphorylation but was not modi®ed in cells expressing either Tpr-Met D26 or Tpr-Met D47. In agreement with this observation, the electrophoretic mobility of Gab1 phosphorylated by Tpr-Ron, endowed with a catalytic eciency ®ve times lower than Tpr-Met (Santoro et al., 1996) , was increased compared to Gab1 phosphorylated by Tpr-Met wild type (Figure 4d ).
These results indicate that the full kinase activity of Tpr-Met, and thus the transforming ability of this oncogene, requires the presence of the last 26 amino acids of Met b subunit.
The insertion of the M1250T point mutation releases the Tpr-Met kinase from the requirement of the positive role played by the last 26 amino acids Novel mechanisms that convert Met into an oncogenic form have been identi®ed. Single point mutations into the Met kinase domain confer transforming ability to Met (Schmidt et al., 1997 (Schmidt et al., , 1998 . Among these mutations, the most active in transformation is M1250T. Interestingly, this point mutation is located in codon homologous to the one mutated in the kinase receptor Ret (M918T). The mutation M918T in the Ret proto-oncogene is associated with multiple endocrine neoplasia type 2B (MEN2B) and sporadic medullary thyroid carcinoma (Hofstra et al., 1994) . This suggests that alteration of this residue is a critical event in deregulating tyrosine kinase receptors. To investigate the biochemical and the biological role of the Cterminal tail in the mutated forms of Met, we have inserted this point mutation into Tpr-Met and Tpr-Met D26 (here called Tpr-Met M1250T and Tpr-Met M1250T D26, respectively). Then, we performed a focus formation assay in NIH3T3 cells with these dierent forms of Tpr-Met. As shown in Figure 5a , Tpr-Met M1250T is 35+5% more ecient in transformation than TprMet. Surprisingly, Tpr-Met M1250T and Tpr-Met M1250T D26 induced the formation of the same number of foci. In agreement with this observation, Tpr-Met M1250T and Tpr-Met M1250T D26 phosphorylated Gab1 in vivo to the same extent but more eciently compared to Tpr-Met. This indicates that the insertion of the M1250T mutation overcomes the requirement of the last 26 amino acids of the Met tail for up-regulation of the receptor kinase activity.
Discussion
The deregulated activation of the Met proto-oncogene mediates cell transformation and confers invasive and metastatic properties to cancer cells (for a review see Comoglio et al., 1999; Furge et al., 2000) . Gene rearrangement, autocrine stimulation, receptor overexpression and point mutations convert Met to oncogenic forms (Cooper et al., 1984; Park et al., 1986; Di Renzo et al., 1992 Ferracini et al., 1995; Rong et al., 1994a,b; Schmidt et al., 1997 Schmidt et al., , 1998 . Under physiological conditions, ligand binding and receptor dimerization drive Met activation and phosphorylation of two tyrosines located in the C-terminal tail (Y 1349 VHV-Y 1356 VNV). These phosphorylated tyrosines couple the receptor to the intracellular eectors (Graziani et al., 1991; Ponzetto et al., 1994; Pelicci et al., 1995; Weidner et al., 1996; Boccaccio et al., 1998) . It has been shown that the interaction between the Met docking site and the kinase domain inhibits the activity of the receptor . In fact, Met phosphorylation is reduced by 80% after cell Figure 4 Deletion of the last 26 amino acids of Tpr-Met impairs its ability to transform cells and to phosphorylate Gab1. (a) The transforming activity of Tpr-Met wt and Tpr-Met mutants was determined by focus forming assay in NIH3T3 ®broblasts. Cells were transfected with either 1 mg of the empty vector (pBabe) or 1 mg of expression vector containing wild type or the indicated TprMet mutants. Foci were scored 3 weeks after transfection following Giemsa staining. Results are expressed as percentage of focus forming ability relative to Tpr-Met wild type (100%). Bars indicate standard deviation of three independent experiments. (b) COS-7 cells transfected with Gab-1 and Tpr-Met wild type or mutants, as indicated, were starved for 15 h. The clari®ed lysates were incubated with antibodies to Gab1 preadsorbed on protein G-Sepharose. The pellets were then washed twice and samples were analysed by Western blotting with anti-Gab1 antibodies, anti-phosphotyrosine antibodies and anti-h-Met antibodies, as indicated. (c) Phosphorylated Gab1 and total Gab1 were quanti®ed by densitometry using Molecular Dynamics ImageQuant software. Data are expressed as percentage of Gab1 phosphorylation compared to Tpr-Met wild type and are normalized for amounts of total Gab1. (d) COS-7 cells transfected with Gab1 alone or Gab1 with Tpr-Met or Tpr-Ron, as indicated, were starved for 15 h. One aliquot of the total lysates was analysed by Western blotting with anti-Gab1 antibodies treatment with a peptide derived from Met tail. Moreover, the activity of this amino acid sequence seems to be highly speci®c since the same peptide can induce an inhibition of only +50% of the phosphorylation of the homologous receptor Ron . Furthermore, the evaluation of the catalytic activity versus an exogenous substrate (MBP) of a TprMet mutant in which the C-terminal part was swapped with the corresponding domain of Ron (called TprMet CRon ) revealed an increased ability of Tpr-Met CRon to phosphorylate MBP (Santoro et al., 1996) . This indicates that the interaction between the Ron docking site and the Met kinase domain only slightly inhibits Met activity.
We now show that the last 26 amino acids of the Met receptor, localized after the docking site, play a positive role in the regulation of receptor kinase activity. Indeed, Met D26 phosphorylates MBP and Gab1 to a lesser extent compared to the wild type forms. One explanation could be that this domain plays a role in the Gab1 recruitment by Met. However, this is not the case since Met and Met D26 were equally able to interact with Gab1. The involvement of a tyrosine phosphatase has also been investigated. The treatment of cells expressing Tpr-Met wild type or TprMet mutants with a tyrosine phosphatase inhibitor (Sodium orthovanadate), did not qualitatively alter the level of Gab1 phosphorylation in Tpr-Met versus mutant expressing cells (data not shown). This suggests that the deletion of the last 26 amino acids does not aect Gab1 de-phosphorylation. Nevertheless, we cannot rule out a role of phosphatases in dephosphorylation of speci®c sites. An alternative hypothesis could be that this domain is involved in the release of autoinhibition mechanisms and, thus, confers to the receptor its full enzymatic activity.
We also show that while full kinase activity is dispensable for Met-mediated invasiveness, it is critical for the transforming ability. Previous studies have shown that the level of the kinase activity required to elicit transformation is higher than that necessary for invasion. This has been clearly shown, for example, in the case of Ron. The constitutive activation of Ron, possessing a catalytic eciency ®ve times lower than activated Met, promotes invasion but not transformation (Santoro et al., 1996) . As expected, up-regulation of the Ron enzymatic activity confers transforming properties to this kinase . Accordingly, it is likely that the decrease of Met kinase activity, due to the deletion of its last 26 amino acids, impairs its transforming ability but is sucient for Met to elicit invasion. Another explanation could be that, since Tpr-Met D26 lacks one autophosphorylation site (Y 1365 ), Tpr-Met-mediated transformation could require the recruitment of a speci®c SH2-containing transducer by this phosphotyrosine. However this is not the case since the mutation of this single tyrosine has no eect on the transforming ability of Tpr-Met .
Other mechanisms, apart from the chromosomal rearrangement (Tpr-Met) induced by a chemical carcinogen, convert Met into an oncogenic form. Single point mutations into the kinase domain confer to Met transforming ability (Schmidt et al., 1997 (Schmidt et al., , 1998 . Among these mutations, the most active in transformation is M1250T. Interestingly, we show here that the insertion of the M1250T point mutation in Tpr-Met D26 releases the kinase from the requirement of the positive role played by its tail. Since the insertion of this point mutation (M1250T) in Met and Tpr-Met up-regulates their kinase activity Maritano et al., 2000) , the regulation by Figure 5 The insertion of M1250T point mutation in Tpr-Met D26 rescues the full transforming ability and kinase activity. (a) The transforming activity of mutant Tpr-Met was determined by focus forming assay in NIH3T3 ®broblasts, as described in the Materials and methods section. Results are expressed as percentage of focus forming ability relative to Tpr-Met (100%). (b) COS-7 cells transfected with Gab-1 and Tpr-Met wild type or mutants, as indicated, were starved for 15 h. The clari®ed lysates were incubated with antibodies to Gab1 preadsorbed on protein G-Sepharose. The pellets were then washed twice and samples were analysed by Western blotting with anti-Gab1 antibodies, anti-phosphotyrosine antibodies and anti-h Met antibodies, as indicated the C-terminal tail could become unnecessary. Since in Ret the homologous mutation modi®es a number of receptor properties including substrate speci®city, ligand-dependent activation, auto-phosphorylation sites and interaction with signal transducers, it is possible that the M1250T mutation exerts similar eects in the Met system (Santoro et al., 1995; Asai et al., 1996; Borrello et al., 1995; Iwashita et al., 1996) . Resolution of the tri-dimensional structure of the insulin receptor has shown that phosphorylation of tyrosines in the activation loop releases the inhibition of both substrate and ATP binding and drives receptor activation (Hubbard et al., 1994 (Hubbard et al., , 1997 . In the Met system, phosphorylation of Y 1234 and Y 1235 correlates with the up-regulation of Met activity and it is required to unleash the transforming potential Naldini et al., 1991; Longati et al., 1994; . However, it has recently been shown that the activity of Tpr-Met M1250T is partially independent of the phosphorylation of both tyrosines (Y 1234 and Y 1235 ) (Maritano et al., 2000) . It is thus likely that the M1250T mutation may interfere with the mechanisms of auto-inhibition of Met in two ways: (a) by increasing accessibility of the substrate-binding pocket; and/or (b) by partially dislodging the activation loop from the active site.
In conclusion, we show that the C-terminal domain of Met not only couples the receptor to its transducers, but also plays an important role in the regulation of the kinase activity. The low sequence homology among the corresponding domains of Met, Ron and c-Sea suggests that the tails play a dierent role for the three receptors.
Materials and methods

Reagents and antibodies
All reagents used were from Fluka (FlukaChemie, AG). Reagents for SDS ± PAGE were from Bio-Rad (Biorad Laboratories). [g-32 P]ATP was purchased from Amersham Italia. Recombinant HGF was obtained from baculovirusinfected SF-9 cells. The monoclonal anti-human HGF receptor antibodies (DQ 13 and DL 21) were puri®ed from ascites¯uids of hybridoma from mice, and kindly provided by M Prat and R Albano. Anti-phosphotyrosine antibodies and anti-Gab1 antibodies were purchased from UBI (Lake Placid, NY, USA).
Plasmid construction
The Trk-Met constructs were generated as previously described . All point mutations of Met, Tpr-Met and Trk-Met were generated by site-directed mutagenesis using the Stratagene QuikChange Kit (La Jolla, CA, USA) and the presence of point mutations was veri®ed by DNA sequence analysis (F 1344 codon and Y 1365 codon were replaced by a Amber codon, respectively; M 1250 codon was replaced to T codon). The wild type and mutated Met cDNAs were subcloned into pCEV29.1 expression vector. The wild type and mutated Tpr-Met cDNAs were subcloned into pBABE or pcDNA3 expression vectors. The wild type and mutated Trk-Met cDNA were subcloned into pMT2 expression vector. The Tpr-Ron cDNA was subcloned into pMT2 expression vector.
The mouse Gab1 cDNA subcloned into pBluescript-SK was a gift from Dr W Birchmeier. To produce the GST fusion protein, the Gab1 Not-1-fragment was inserted inframe into pGEX-4T1 vector (Pharmacia Biotech Inc). Gab1 cDNA was subcloned into the pcDNA3 expression vector (Invitrogen, CA, USA).
Cell culture
NIH3T3 and COS-7 cells were purchased from ATCC (American Type Culture Collection). MLP29 is an epithelial cell line derived from mouse liver oval cells (Medico et al., 1996) . Cells were cultured in Dulbecco's modi®ed Eagle's medium supplemented either with 5% fetal calf serum (Sigma Chemical Co., St. Louis, MO, USA) or 5% calf serum (Colorado Serum Company) and maintained at 378C in a 5% CO 2 -humidi®ed atmosphere. MLP-29 stable cell lines expressing Trk-Met wild type or mutants were obtained by cotransfection, using the calcium phosphate precipitation technique (CellPhect, Pharmacia, Uppsala, Sweden), of each pMT2 expression plasmid with an expression vector carrying the resistance to Puromycin. The selection was performed in growth medium supplemented with 1.5 mg/ml of Puromycin. NIH3T3 stable cell lines expressing Met wild type or mutants were obtained by transfection of each pCEV29.1 expression plasmid using the calcium phosphate precipitation technique. The selection was performed in growth medium supplemented with 0.8 mg/ml of G-418 sulfate (geneticin; GIBCO BRL Life Technologies, USA). After 2 weeks, the expression of the respective recombinant proteins was tested by Western blot analysis.
In vitro phosphorylation assays
Antibodies anti-Met (4 mg/sample) were incubated with protein G-Sepharose for 1 h at 48C. Lysates from NIH3T3 cells expressing Met wild type or mutants were incubated with the anti-Met antibodies for 2 h. The pellets were washed twice with 20 mM HEPES, 100 mM NaCl containing 1% (vol/vol) of Triton X-100. The MBP (increasing concentrations as indicated) was mixed with pellets containing the immunopuri®ed Met. The phosphorylation reaction was initiated by addition of 20 mM HEPES, 100 mM NaCl, 5 mM MnCl 2 , 5 mM MgCl 2 , 15 mM [g-32 P] (2.5 Ci/mmol) ATP. After 20 min, the reaction was stopped by addition of Laemmli sample buer and samples were separated by SDS ± PAGE on a dual concentration (8 ± 12%) resolving gel. The 12% polyacrylamide half of the gel containing [g-32 P]MBP was dried and exposed for autoradiography; the 8% acrylamide half of the gel was used for Western blotting with anti-Met antibodies. The Western blot ®lm and the autoradiograph were scanned for signal intensity using Molecular Dynamics ImageQuaNT version 4.1a software. After correction for Met expression, the results were expressed as percentage of MBP phosphorylation relative to Met wild type. (100% corresponds to the amount of [g- changed after 5 h and HGF (100 units/ml) or NGF (100 ng/ ml) was added as indicated. After 12 h, the cells were ®xed with glutheraldeyde and stained with crystal violet. The morphogenic activity of the MLP29 cultures was analysed as previously described (Medico et al., 1996) . Brie¯y, the cells were harvested from cultures using trypsin-EDTA and suspended at a concentration of 10 5 cells per ml in collagen solution containing type I collagen gel (3 mg/ml) (Collaborative Biomedical Products; Becton Dickinson Labware), 10X DMEM (Gibco BRL), and 0.5 M HEPES (pH 7.4). Aliquots (100 ml) of the cell suspension were dispensed in 96-well microlitter plates and allowed to gel for 15 min at 378C before adding 200 ml of DMEM with 20% FCS. After 12 h, HGF (100 units/ml) or NGF (100 ng/ml) was added as indicated. The medium was changed every 2 days. After 5 to 7 days the branching tubulogenesis response was evaluated.
Production of fusion proteins
The pGEX-Gab1 was expressed in Escherichia Coli. Expression of recombinant proteins was induced with 0.1 mM isopropyl-b-D-thiogalactopyranoside for 3 h. Bacteria were lysed with 20 mM Tris, 1 M NaCl, 0.2 mM EDTA, 0.2 mM EGTA, 1 mg/ml lysozyme, 0.5 mM phenyl-methylsulfonyl uoride, 100 U/ml aprotinin, 20 mM leupeptin (pH 7.4) for 30 min in ice, sonicated three times and frozen in liquid nitrogen. Lysates were centrifuged (30 000 g for 30 min at 48C), and the supernatants were incubated with glutathioneSepharose (Pharmacia) for 1 h at 48C. The fusion proteins were eluted with 50 mM glutathione and 100 mM HEPES (pH 8).
Pull down of Trk-Met wild type and mutants by GST-Gab1
After serum-starvation, MLP 29 cells expressing wild type or mutant Trk-Met were treated with NGF (200 ng/ml) for 10 min. Cells were subsequently washed with ice-cold Stop buer (20 mM TRIS, 150 mM NaCl, 5 mM EDTA, 150 mM NaF, and 2 mM sodium orthovanadate, pH 7.4) before solubilization for 30 min at 48C in EB buer (20 mM TRIS, 150 mM NaCl, 5 mM EDTA, 150 mM NaF, 2 mM sodium orthovanadate, 0.5 mM phenylmethylsulfonyl¯uoride, 100 U/ml aprotinin, 20 mM leupeptin, 10% glycerol, and 1% (vol/vol) Triton X-100, pH 7.4). Clari®ed lysates obtained after centrifugation (15 min at 15 000 g at 48C) were incubated either with GST (5 mg), or with Gab1 (5 mg) obtained as GST fusion proteins immobilized on glutathioneSepharose (Pharmacia). After 2 h at 48C, Sepharose beads were washed with EB buer and bound proteins were separated on SDS ± PAGE using an 8% resolving gel and transferred to nitrocellulose ®lters (Hybond, Amersham, UK). The membrane was blocked with saline buer (10 mM Tris, 140 mM NaCl, pH 7.4) containing 5% (wt/vol) BSA for 2 h at 228C and probed with the anti-phosphotyrosine antibodies at 1 mg/ml. Speci®c binding was detected by an Enhanced Chemiluminescence System (ECL, Amersham).
Focus forming assay
NIH3T3 cells were transfected at a density of 1.5610 5 / 100 mm plate by the calcium phosphate method, using 40 mg/ plate of carrier DNA (calf thymus high molecular weight DNA, Boehringer Mannheim) with either 1 mg of the empty vector or 1 mg expression vector containing wild type or the indicated mutant Tpr-Met. For detection of foci, cells were maintained in DMEM containing 5% calf serum (Colorado Serum Company), and foci were scored 3 weeks after transfection following ®xation in 3% paraphormaldehyde and Giemsa staining. The results were expressed as percentage of focus forming ability relative to Tpr-Met (100%). Tpr-Met yields approximatively 20 foci/mg.
Phosphorylation of Gab1 in intact cells
After serum-depletion, COS-7 cells co-transfected with Gab1 (2 mg) and with Tpr-Met wild type or mutants (8 mg), as indicated, were washed with ice-cold Stop buer, before solubilization for 30 min at 48C in EB buer. Clari®ed lysates were incubated for 3 h at 48C with anti-Gab1 antibodies preadsorbed on protein-G Sepharose (4 mg of antibodies/ sample). Pellets washed with EB buer were resuspended in Laemmli sample buer and separated by SDS ± PAGE using an 8% resolving gel, before transfer to a nitrocellulose membrane. The membranes were probed with the anti-Gab1 antibodies and anti-phosphotyrosine antibodies (at 1 mg/ml), as indicated.
Abbreviations HGF, hepatocyte growth factor; GRB-2, growth factor receptor-bound protein 2; Gab1, GRB2 associated binder-1; PI 3 kinase, phosphoinositide 3 kinase; STAT, signal transducer and activator of the transcription; SHPTP, SH2 containing Phosphotyrosine phosphatase; SHC, Src homology/collagen; SH2, Src homology 2; p85, the 85 kDa regulatory subunit of PI 3 kinase; pr, precursor; GST, glutathione S-transferase
